

GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE, VAPI - 396 195. DIST. VALSAD, GUJARAT, INDIA. TEL : 0260-2430027 Email : hrm@gtbl.in.net CIN No.: L24230GJ1981PLC004878

GTBL: CS: BSE-CORR/2022-23

03rd February 2023

BSE Limited, P. J. Towers, Dalal Street, Mumbai-400001

Dear Sir/Madam,

Sub: Outcome of Board Meeting under Reg. 30 of SEBI (LODR) Regulations, 2015

Meeting Commencement Time	: 10:15 A.M
Meeting Conclusion Time	:10:57A.M.

The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results of the Company for the Quarter ended 31st December, 2022.

A copy of Unaudited Financial Results of the Company for the Quarter ended 31st December, 2022 together with Limited Review Report is enclosed herewith.

This may be taken as compliance under the Listing Regulations.

Kindly take the same on record.

Thanking you,

Yours Faithfully,

For GUJARAT THEMIS BIOSYN LIMITED

Raĥul Soni Company Secretary & Compliance Officer





Chartered Accountants

3rd & 4th Floor, Vaastu Darshan,
'B' wing, Above Central Bank of India,
Azad Road, Andheri (East).
Mumbai - 400 069.
Tel. : 022 - 6191 9293 / 222 / 200
Fax : 022 - 2684 2221 / 6191 9256
E-mail : admin@gmj.co.in info@gmj.co.in

Independent Auditor's Review report on quarterly and year to date unaudited financial results Of Gujarat Themis Biosyn Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review report to The Board of Directors GUJARAT THEMIS BIOSYN LIMITED

We have reviewed the accompanying statement of unaudited financial results of <u>Gujarat Themis Biosyn</u> <u>Limited</u> ('the Company') for the quarter ended December 31, 2022 and year to date from April 1, 2022 to December 31, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulation") read with circular (Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019) issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, to the extent applicable.

This starement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





Based on our review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

MUMBAI

For GMJ & Co Chartered Accountants FRN: 103429W

 CA Sanjeev Maheshwari
 ALD M

 Partner
 M. No.: 038755

 UDIN:-230387 5586∨₩ K41320

Place : Mumbai Date : February 3rd, 2023

GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2022

Sr.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended	
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022	
No.		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Income from operations	2,816.50	4,769.09	1,860.35	12,080.03	8,609.05	11,485.39	
Ш	Other Income	180.63	139.64	69.33	462.52	254.11	405.01	
111	Total Income (I+II)	2,997.13	4,908.73	1,929.68	12,542.55	8,863.16	11,890.40	
IV	Expenditure							
	(a) Cost of raw material consumed	743.75	766.43	642.94	2,277.36	1,855.93	2,174.63	
	(b) Purchases of stock-in-trade	2) 2)		-	-		
	(c) Changes in inventories of Finished Goods, Work-in-			1				
	Progress and Stock in Trade	(544.37)	400.41	(854.57)	174.37	(817.20)	(513.07)	
	(d) Employee benefits expense	194.87	190.59	186.22	560.17	542.85	708.36	
	(e) Finance Cost	7.10	4.24	32.75	17.58	64.91	82.78	
	(f) Depreciation and Amortisation expenses	65.81	57.86	57.14	180.65	168.94	223.30	
	(g) Other Expenses							
	i) Stores and spares	133.66	105.51	96.53	353.05	296.07	427.65	
	ii) Power	447.56	457.47	421.90	1,335.16	1,218.88	1,489.85	
	iii) Fuel	188.59	183.15	190.65	577.65	487.68	594.68	
	iv) Water	26.48	23.50	23.67	77.36	70.61	88.33	
	v) Other expenditure	414.87	201.89	173.41	795.81	457.68	710.44	
	Total Expenses	1,678.33	2,391.05	970.65	6,349.17	4,346.35	5,986.95	
v	Profit (Loss) before Exceptional Items and Tax (III-IV)	1,318.80	2,517.68	959.03	6,193.38	4,516.80	5,903.45	
VI	Exceptional items	-	-	-	-	-	-	
VII	Profit (Loss) before Tax (V-VI)	1,318.80	2,517.68	959.03	6,193.38	4,516.80	5,903.45	
VII		2,020,00	2,527100		0,200.00	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0,000.10	
VIII	Tax expenses							
	(a) Current Tax	320.36	621.23	243.55	1540.71	1132.23	1,533.80	
	(b) Deferred Tax	17.70	26.55	3.42	25.00	1.05	7.24	
	(c) Income Tax of earlier years		-	-	-		() + (
IX	Net Profit (Loss) after tax (VII-VIII)	980.74	1,869.90	712.06	4,627.67	3,383.53	4,362.42	
×	Other Comprehensive Income							
	(a) Items that will not be reclassified to Profit or Loss							
	(i) remeasurement of defined benefit plans;	(2.70)	(2.70)	(1.04)	(8.09)	(3.11)	(10.79)	
	(ii) Income Tax relating to items that will not be reclassified							
	to Profit or Loss	0.70	0.70	0.27	2.10	0.81	2.81	
	(b) Items that will be reclassified to Profit or Loss							
	(i) Income Tax relating to items that will be reclassified to	1						
	Profit or Loss	-	-	-				
XI	Total Comprehensive Income for the period (IX+X)	978.75	1,867.91	711.29	4,621.68	3,381.22	4,354.44	
XII	Paid-up equity share capital	726.44	726.44	726.44	726.44	726.44	726.44	
XIII	Other Equity	-	-	2	-	-	9,605.70	
XIV	Earnings Per Share (Basic and Diluted)	6.75	12.87	4.90	31.85	23.29	30.03	



GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Notes:

- 1 The financial results for the quarter and nine months ended December 31, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 3rd February, 2023.
- 2 The Company operates only in one Business Segment i.e. manufacturing Bulk Drugs, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- 3 The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 4 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and postemployment benefits received Presidential assent in September 2020. The Code has been notified in the Gazette of India. However, the date from which it will be implemented has reportedly not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 5 During the Quarter, the Board has declared an Interim dividend for Financial Year 2022-2023 of Rs.4.4/- per equity share of the face value of Rs. 5/- at its Board Meeting held on 21st Nov. 2022.
- 6 Figures of previous period/year' have been regrouped / rearranged, wherever considered necessary.

For GUJARAT THEMIS BIOSYN LIMITED Dr. DINESH PATEL

Place: Mumbai Date : 3rd February, 2023 Dr. DINESH PATE Chairman DIN : 00033273

